36 related articles for article (PubMed ID: 15368327)
21. Ribozyme- and siRNA-mediated suppression of RGS-containing RhoGEF proteins.
Wang Q; Liu M; Kozasa T; Rothestein JD; Sternweis PC; Neubig RR
Methods Enzymol; 2004; 389():244-65. PubMed ID: 15313570
[TBL] [Abstract][Full Text] [Related]
22. Short interfering RNA (siRNA) as a novel therapeutic.
Pushparaj PN; Melendez AJ
Clin Exp Pharmacol Physiol; 2006; 33(5-6):504-10. PubMed ID: 16700886
[TBL] [Abstract][Full Text] [Related]
23. Antisense strategies in the treatment of leukemias.
Calabretta B; Skorski T; Ratajczak MZ; Gewirtz AM
Semin Oncol; 1996 Feb; 23(1):78-87. PubMed ID: 8607034
[TBL] [Abstract][Full Text] [Related]
24. RNA interference as a potential tool in the treatment of leukaemia.
Borkhardt A; Heidenreich O
Expert Opin Biol Ther; 2004 Dec; 4(12):1921-9. PubMed ID: 15571454
[TBL] [Abstract][Full Text] [Related]
25. Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi.
Deveraux QL; Aza-Blanc P; Wagner KW; Bauerschlag D; Cooke MP; Hampton GM
Semin Cancer Biol; 2003 Aug; 13(4):293-300. PubMed ID: 14563124
[TBL] [Abstract][Full Text] [Related]
26. [Mechanisms for oriented cell division in mammalian cells].
Toyoshima F
Seikagaku; 2012 Feb; 84(2):81-91. PubMed ID: 22550898
[No Abstract] [Full Text] [Related]
27. Oncogenic Signaling in Tumorigenesis and Applications of siRNA Nanotherapeutics in Breast Cancer.
Kamaruzman NI; Aziz NA; Poh CL; Chowdhury EH
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31064156
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes.
Ohba H; Zhelev Z; Bakalova R; Ewis A; Omori T; Ishikawa M; Shinohara Y; Baba Y
Cancer; 2004 Sep; 101(6):1390-403. PubMed ID: 15368327
[TBL] [Abstract][Full Text] [Related]
29. [CML with mu-BCR/ABL mRNA: clinical characteristics of our three cases and 26 reported cases].
Ito T
Rinsho Ketsueki; 2003 Apr; 44(4):234-41. PubMed ID: 12784656
[No Abstract] [Full Text] [Related]
30. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins.
Perrotti D; Calabretta B
Oncogene; 2002 Dec; 21(56):8577-83. PubMed ID: 12476304
[TBL] [Abstract][Full Text] [Related]
31. Involvement of the abl oncogene in human chronic myelogenous leukemia.
Witte ON
Princess Takamatsu Symp; 1986; 17():143-9. PubMed ID: 3332006
[TBL] [Abstract][Full Text] [Related]
32. Translational regulation by the p210 BCR/ABL oncoprotein.
Perrotti D; Calabretta B
Oncogene; 2004 Apr; 23(18):3222-9. PubMed ID: 15094772
[TBL] [Abstract][Full Text] [Related]
33. RNA molecules as anti-cancer agents.
Friedrich I; Shir A; Klein S; Levitzki A
Semin Cancer Biol; 2004 Aug; 14(4):223-30. PubMed ID: 15219615
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
